The latest news and views from bridge therapeutics

09/05/18 Bridge Therapeutics Team to Speak on Tackling a Key Source of the Opioid Crisis

Dr. Greg Sullivan, Chief Scientific Officer, Dr. Dave Bergstrom. Chief Operations Officer, and Tim Peara of will be speaking about how Bridge Therapeutics’ lead investigational drug could be a key part of ending the opioid crisis.

September 4, 2018

Each year 70 million Americans will take an opioid for pain. Of these, 17 million take a strong opioid daily. It is these 17 million patients who are most at risk of addiction disorders leasing to shattered relationships, overdoes, and possibly death. 70% of opioid overdose victims started by abusing pain medication. A key part to ending the Opioid Crisis will be providing a safer therapy than opioids for chronic pain.

Read the Full Article Here

08/21/18 Medication-Assisted Treatments Underused in Patients With Opioid Use Disorder

“A great part of the tragedy of this opioid crisis is that, unlike in previous such crises America has seen, we now possess effective treatment strategies that could address it and save lives,” Nora Volkow, MD, the director of the National Institute on Drug Abuse, wrote in an editorial accompanying the study (Ann Intern Med 2018 Jun 19). “Yet tens of thousands of people die each year because they have not received these treatments.”  

August 20, 2018 

According to the National Institutes of Health–funded study, adults prescribed buprenorphine had a decreased mortality rate of 38%, compared with patients not receiving any medication-assisted treatment over the one-year study period.

Read the full article here

08/17/18 To fight the opioid crisis, the US needs to look at what works

In this article the Washington Examiner discusses how buprenorphine/naloxone combination should be readily available and could act as a key defense against the on going opioid problem in the U.S.

August 16, 2018

Key to understanding how buprenorphine helps is an understanding of the difference between physical dependence and addiction. This can be a confusing distinction, as the terms are sometimes used interchangeably. Addiction is essentially an uncontrollable craving and an inability to control use. Dependence, on the other hand, is the term used to describe the physical reliance on opioids.

Read full article here

07/24/18 Expanding primary care buprenorphine treatment could curb opioid overdose crisis

In this article “Primary Care and the Opioid-Overdose Crisis — Buprenorphine Myths and Realities,” Sarah Wakeman, MD, medical director of the Massachusetts General Hospital Substance Use Disorders Initiative and Michael Barnett, MD, of the Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, discuss how “to have any hope of stemming the overdose tide, we have to make it easier to obtain buprenorphine than to get heroin and fentanyl”. The authors believe “there’s a realistic, scalable solution for reaching the millions of Americans with opioid use disorder: mobilizing the primary care physician (PCP) workforce to offer office-based addiction treatment with buprenorphine, as other countries have done.”

July 4, 2018

Expanding the availability of medication treatment for opioid use disorder in primary care settings would be a major step toward reducing overdose deaths, write the two physicians specializing in addiction medicine and health care delivery in the July 5 issue of New England Journal of Medicine.

Read the full article here

07/20/18 How a brain gets hooked on opioids

In this article by PBS explains how traditional opioids interact with the receptors in the brain to produce analgesia (pain relief), constipation, depression, and euphoria. Cathy Cahill PhD, a pain researcher at UCLA also explains how those with chronic pain taking traditional opioids experience big swings of emotion due to the euphoria and subsequent dysphoria as the opioids enter and leave the receptors.  The changes in emotions when coupled with mental health can make a patient more vulnerable to opioid addiction.

October 9, 2017

A 2017 study found most patients — 81 percent — whose addiction started with a chronic pain problem also had a mental health disorder. Another study found patients on morphine experience 40 percent less pain relief from the drug if they have mood disorder.

Read the full article here

07/19/18 Opioid addiction is keeping a high percentage of people out of the workforce, Fed chairman says

America’s opioid epidemic is exacting a massive human toll that also is impacting the economy, Federal Reserve Chairman Jerome Powell said Tuesday. “From an economic standpoint, some high percentage of prime-age people who are not in the labor force, particularly prime-age males who are not in the labor force, are taking painkillers of some kind,” he said.

July 17, 2018

Powell cited research from Princeton economist Alan Krueger, who conducted a survey and found that 44 percent of men reported that they had taken some form of pain medication the previous day.

Read the full article here

07/19/18 Bridge Therapeutics, to Participate in American Chronic Pain Association Roundtable With Agenda for Chronic Pain Drug Development Program

Executives with the innovative late development-stage pharmaceutical startup, Bridge Therapeutics, announced they will be introducing their chronic pain development program at the American Chronic Pain Association (ACPA) Roundtable. The ACPA offers peer support and education in pain management skills to people with chronic pain, along with their families, friends, and healthcare professionals.

July 11, 2018

Alton Kelley, Director of Business Development for Bridge Therapeutics, said this roundtable will give the chronic pain community an opportunity to learn more about Bridge Therapeutics’ current developments on pain relievers and promoting the ACPA’s efforts in fighting chronic pain.

Read the full article here

07/10/18 Pharma Startup, Bridge Therapeutics, Will Unveil Its Chronic Pain Drug Development Program at the 2018 Young Startup Ventures Summit in New York

Executives with the innovative late development-stage pharmaceutical startup, Bridge Therapeutics, announced they would showcase their chronic pain drug development program to venture capitalists at the 2018 Young Startup Ventures Summit in New York.

July 9, 2018

More than 150 venture capitalists will hear pitches and programs from various companies and startups in fields ranging from fintech to life sciences. The 2018 New York Venture Summit will take place at Convene in New York on July 10-11. Tim Peara said this forum would enable venture capitalist to hear how Bridge’s work towards developing a safer alternative for chronic pain has been progressing.

Read More

06/27/18 The NIH Announces New Research Initiative to Fight Opioid Addiction

The National Institutes of Health (NIH) recently announced a new set of research priorities around addiction and pain research in efforts to combat the nation’s opioid crisis.

June 22nd, 2018

The HEAL (Helping to End Addiction Long-term) Initiative was launched by the NIH with support from the president and the Department of Health and Human Services. Under this ambitious new research program, the NIH will invest resources to aid the discovery of scientific solutions for opioid addiction and pain management.

Read the full article here

06/13/18 BIO2018 Makes History in Boston

Bridge Builds Connections at World’s Largest Business Partnering Event.

June 7, 2018

The Bridge Therapeutics Team traveled to Boston for the BIO International Convention. Bridge met with investors as well as worked to attain other sources of capital. The team, also, met with vendors and service providers in preparation for the launch of their lead investigational drug BT-205. Bridge’s Tim Peara, Alton Kelley, and Dave Bergstrom were a part of the nearly 47,000 partnering meetings that occurred making them a part of the Guinness Book of World Records “Largest Business Partnering Event”.

“We’re really hoping to work with investors on financing so we can get our drug to the FDA,” said Alton Kelley, the firm’s director of business development. “We’re going to need a little more capital to get it through the finish line.”

Read the full article here


For more information about Bridge Therapeutics please contact us today using the form below.